Korea's Takeda Pharmaceutical Appoints Kim Mi-seung, New Director of Anti-cancer Drug Business Division
Apr 17, 2025
|
Kim Mi-seung, the new general manager who was appointed on April 15, is an expert who has been performing major functions such as marketing, medical, and academic sales, focusing on anticancer drugs at home and abroad for more than 20 years. In particular, it has led the overall establishment and implementation of product strategies for blood and solid cancer treatments and has shown strength in collaboration and performance creation between departments.
Until recently, Kim was in charge of Amgen Korea's anticancer drug division and led the market entry and performance creation by performing marketing, medical and sales duties in various multinational pharmaceutical companies' anticancer drug divisions. In addition, he works as a clinical pharmacist at Samsung Seoul Hospital and National Cancer Center and is evaluated as having field-based expertise based on a deep understanding of the patient treatment site.
Kim earned a bachelor's degree in pharmacy from Chung-Ang University and later completed a global Executive MBA course jointly run by Sungkyunkwan University and Indiana University's Kelly School of Business, expanding strategy establishment and interfunctional collaboration capabilities in a complex business environment. In addition, it has a Board Certified Oncology Pharmacist (BCOP) qualification, so international clinical expertise is also recognized in the field of chemotherapy.
Park Kwang-kyu, CEO of Takeda Pharmaceutical Co., Ltd., said "Anti-cancer drug business division is Takeda KoreaAs a major strategic business for pharmaceuticals, it plays a key role in patient-centered innovation and expanding access to treatment""As a leader with abundant experience and integrated perspective in the field of anticancer, we expect to lead the division's competitiveness in the future and contribute to providing innovative treatment options to more patients," said Kim Mi-seung, new general manager of the anticancer division."
This article was translated by Naver AI translator.
